

Product Name: ABT-199 Revision Date: 09/20/2023

## **Product Data Sheet**

### **ABT-199**

Cat. No.: A8194

CAS No.: 1257044-40-8

Formula: C45H50CIN7O7S

**M.Wt:** 868.44

**Synonyms:** ABT199, ABT 199, GDC0199, GDC-0199

Target:ApoptosisPathway:Bcl-2 FamilyStorage:Store at -20°C

# Solvent & Solubility

≥43.42 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	1.1515 mL	5.7575 mL	11.5149 mL
	5 mM	0.2303 mL	1.1515 mL	2.3030 mL
	10 mM	0.1151 mL	0.5 <mark>7</mark> 57 mL	1.1515 mL

Please refer to the solubility information to select the appropriate solvent.

## **Biological Activity**

Shortsummary	Bcl-2 inhibitor, potent and selective		
IC <sub>50</sub> & Target	< 0.010 nM (Ki) (Bcl-2)	al <sup>Q</sup> com	
	Cell Viability Assay	O E Jacobia	
	Cell Line:	normal human B cells, as well as CD4+and CD8+ T cells	
In Vitro	Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining	
		a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or	
		shake it in the ultrasonic bath for a while. Stock solution can be stored below	
		-20°C for several months.	
	Reacting conditions:	24h ;4 μM	

	Applications:	We first determined the in vitro sensitivity to ABT-199 of normal human B cells,				
		as well as CD4+and CD8+ T cells in peripheral blood sampled from healthy				
		donors (n=9). Significantly, normal peripheral B cells were intrinsically more				
		sensitive (~1000-fold) to ABT-199 than either T-cell subset (mean ABT-199				
	a long	LC50±s.e.m. for B cells, CD4 T cells and CD8 T cells were 3.0 ±0.9 nM,				
	Apoc the train	2.5±0.6 μM and 1.3±0.7 μM , respectively; B versus CD4 T cells: P=0.008; and				
	e Petetion.	B versus CD8 T cells: P=0.004). The result shown that normal human				
	Ratio Company	peripheral blood B cells are highly sensitive to ABT-199, unlike T cells and				
		myeloid cells.				
	Animal experiment					
In Vivo	Animal models:	Eμ-Myc mice				
	Dosage form:	100 mg/kg ; Oral taken				
	Applications:	We examined the effect of short-term treatment with ABT-199 (used at 100				
	40.	mg/kg) on the lymphoid subpopulations in vivo to assess this and to model				
	The Unitedian	probable changes during therapy of patients. ABT-199 was administered orally,				
	Ton Expore B	Consistent with our in vitro observations with murine and human cells, the drug				
	A. Julius P. Parlar	substantially reduced peripheral B cells to a similar extent. These data				
		suggested that because of intrinsic insensitivity to selective Bcl-2 inhibition of				
		key B- and T-precursor cells, longer-term administration of ABT-199 may have				
		an impact on normal lymphopoiesis to a lesser degree.				
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may				
		slightly differ with the theoretical value. This is caused by an experimental				
		system error and it is normal.				

### **Product Citations**

1. Thompson PJ, Shah A, et al. "Targeted

Elimination of Senescent Beta Cells Prevents Type 1 Diabetes." Cell Metab. 2019

Feb 14. pii: S1550-4131(19)30021-X.PMID:30799288

2. Minagawa K, Al-Obaidi M, et al. "Generation of Suicide Gene-Modified

Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy." Methods Mol Biol. 2019;1895:57-73.PMID:30539529

3. Wu S, Fatkhutdinov N, et al. "SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells." Nat Commun.

2018 Oct 8;9(1):4116.PMID:30297712

- 4. Li Q, Deng Q, et al. "Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses." Nat Commun. 2018 Sep 6;9(1):3600.PMID:30190514
- 5. Kim SR, Lewis JM, et al. "BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition." Oncotarget. 2018 Jun 26;9(49):29193-29207.PMID:30018745

See more customer validations on www.apexbt.com.

[1] Khaw S L, Mérino D, Anderson M A, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199[J]. Leukemia, 2014, 28(6): 1207-1215.

### Caution

#### FOR RESEARCH PURPOSES ONLY.

#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

#### **APExBIO Technology**

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



A PE to to the Internal Control of the Internal Contro

